Grant: Discovery Grants Program - Individual
Université du Québec à Montréal
$33,000.00
Unravelling of the metabolism of lipoproteins by the hepatic cell
EF 2010-11
Résumé
Endocytosis is a general term describing the entry in the cell of molecules or particles from the blood circulation. Some receptors as the low density lipoprotein (LDL)-receptor (LDLr) take LDL into the cell and leads to their complete degradation. Others such as the scavenger receptor class B-type I (SR-BI) do the selective uptake of only the cholesteryl esters (CE) of LDL and high density lipoprotein (HDL) thereby allowing the return in blood circulation of lipoproteins depleted in CE by a pathway known as retroendocytosis. Our research program addresses above all SR-BI activity. One of our aims is to define the biochemical effects of SR-BI on LDL. The originality of this aim is that although we know the effects on HDL, no one as yet generated such information on LDL. To achieve this aim, we will generate LDL depleted in CE by injecting LDL in mouse blood circulation. These recovered LDL will then be subjected to biochemical analyses to determine their sizes, densities, charges, oxidative status and sensitivity to oxidation, capacities to accept CE from HDL and to interact with the LDLr. This information is important for species with high concentrations of blood LDL such as ours and because we don't yet know if SR-BI activity on LDL is beneficial. In addition, our results have demonstrated in the past that SR-BI is localized in a different plasma membrane structure in hepatic cells that in other cells. Indeed, we found it associated with lipid rafts. Thus our second aim is to define this raft-based endocytotic pathway in hepatic cells by treating the cells with enzymes, toxins and molecular gene constructions meant at interfering with different proteins associated with rafts. This aim is original and important as it will contribute to the knowledge on the intracellular pathway mediated by SR-BI and may uncover a new cellular pathway that will add to our understanding of general cell endocytosis.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
138110-2010
Name nom
Brissette, Louise
Department département
Sciences biologiques
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5407
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Receptors
Research subject fr
Récepteurs
Partie
1
Nb partie
5
Application title
Unravelling of the metabolism of lipoproteins by the hepatic cell
Keyword
NSERC
Application summary
Endocytosis is a general term describing the entry in the cell of molecules or particles from the blood circulation. Some receptors as the low density lipoprotein (LDL)-receptor (LDLr) take LDL into the cell and leads to their complete degradation. Others such as the scavenger receptor class B-type I (SR-BI) do the selective uptake of only the cholesteryl esters (CE) of LDL and high density lipoprotein (HDL) thereby allowing the return in blood circulation of lipoproteins depleted in CE by a pathway known as retroendocytosis. Our research program addresses above all SR-BI activity. One of our aims is to define the biochemical effects of SR-BI on LDL. The originality of this aim is that although we know the effects on HDL, no one as yet generated such information on LDL. To achieve this aim, we will generate LDL depleted in CE by injecting LDL in mouse blood circulation. These recovered LDL will then be subjected to biochemical analyses to determine their sizes, densities, charges, oxidative status and sensitivity to oxidation, capacities to accept CE from HDL and to interact with the LDLr. This information is important for species with high concentrations of blood LDL such as ours and because we don't yet know if SR-BI activity on LDL is beneficial. In addition, our results have demonstrated in the past that SR-BI is localized in a different plasma membrane structure in hepatic cells that in other cells. Indeed, we found it associated with lipid rafts. Thus our second aim is to define this raft-based endocytotic pathway in hepatic cells by treating the cells with enzymes, toxins and molecular gene constructions meant at interfering with different proteins associated with rafts. This aim is original and important as it will contribute to the knowledge on the intracellular pathway mediated by SR-BI and may uncover a new cellular pathway that will add to our understanding of general cell endocytosis.